Tag: steatotic-liver-disease

Research Context

Follistatin is a secreted protein that binds and neutralizes activins and related TGF-β family ligands. “Follistatin-344” (FST344) refers to a 344–amino-acid isoform; however, most sources in this packet discuss follistatin generally (and sometimes follistatin-like 3, FSTL3), not isoform-specific clinical outcomes for FST344 [pubmed:9785474; pubmed:15253386; pubmed:37739334]. The packet contains:

• Human studies in disease-specific, non-interventional contexts (FLT3/ITD acute myeloid leukemia target/biomarker work; circulating hormone profiling in steatotic liver disease; serum follistatin levels in ovarian endometriosis) [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].
• Multiple reviews on activin/follistatin biology, signaling, inflammation/immunity, and related systems [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318; pubmed:21353885].
• Preclinical/mechanistic reports (cancer cachexia pathway mapping; angiogenin-binding) [pubmed:39116208; pubmed:17991437].
• A nonclinical PK/PD study of an engineered human follistatin variant (not FST344) [crossref:10.1124/jpet.112.0313hia].
• Forensic/analytical detection of black-market FST344 [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

Isoform specificity clarification: the packet does not present isoform-specific clinical data for FST344; conclusions should not assume equivalence between total follistatin, FST344, and FSTL3.

Key Takeaway

The supplied literature offers disease-specific human biomarker/target findings for follistatin but no interventional trials of exogenous FST344. Mechanistic reviews and preclinical studies provide context only and do not establish efficacy, safety, or dosing.

Direct Answer

In this packet, direct human evidence related to follistatin is narrow and disease-specific, focusing on target/biomarker work in FLT3/ITD acute myeloid leukemia, circulating hormone measurements in biopsy-proven steatotic liver disease, and serum levels in ovarian endometriosis cohorts [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1]. None of the cited human studies involve interventional administration of exogenous FST344. Mechanistic reviews describe how follistatin modulates activin/TGF-β pathways, providing context but not clinical outcomes [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318; pubmed:21353885]. Preclinical reports map disease-relevant pathways and protein–protein interactions, and analytical studies document detection of black-market FST344; these do not establish clinical efficacy, safety, or dosing for FST344 [pubmed:39116208; pubmed:17991437; crossref:10.1124/jpet.112.0313hia; pubmed:31758732]. Overall, any conclusions should remain anchored to the specific human populations and endpoints studied and should not be generalized.

Human Evidence (Disease-Specific and Observational)

• FLT3/ITD acute myeloid leukemia: A study identified follistatin as a potential therapeutic target and biomarker in FLT3/ITD AML [pubmed:32134197]. This work concerns endogenous target/biomarker identification and does not test exogenous FST344 in humans.
• Steatotic liver disease and steatohepatitis: A multicenter observational study measured circulating hormones, including follistatin, in biopsy-proven steatotic liver disease and steatohepatitis, providing biomarker data within that specific population [pubmed:37757973]. No interventional FST344 administration was involved.
• Ovarian endometriosis: An observational study reported high serum follistatin levels in women with ovarian endometriosis, consistent with a biomarker association rather than interventional evaluation of FST344 [crossref:10.1016/s1090-798x(10)79409-1].

Review Context and Mechanistic Background (Not Human Outcomes)

• Foundational biology and signaling: Reviews summarize follistatin’s binding to activins and other TGF-β family ligands and activin receptor signaling, framing potential mechanisms relevant to diverse tissues [pubmed:9785474; pubmed:15253386].
• Vascular and metabolic context: Reviews discuss activin/follistatin in atherosclerosis and the roles of follistatin and FSTL3 in metabolic disorders [pubmed:10077456; pubmed:37739334].
• Immune/reproductive and inflammatory context: Activins, follistatin, and immunoregulation in the epididymis, and broader roles in inflammation and immunity, are discussed in review literature [pubmed:31322318; pubmed:21353885].

Important clarifications:

• Isoform specificity: Most reviews address “follistatin” generally; they are not isoform-specific for FST344.
• Distinct proteins: FSTL3 (follistatin-like 3) is mechanistically related but distinct; findings for FSTL3 are not interchangeable with those for follistatin/FST344, and differential actions between follistatin and FSTL3 have been reported [pubmed:37739334; pubmed:15451564].

Preclinical and Analytical/Forensic Findings (Nonclinical)

• Cachexia pathway mapping: A single-nucleus study delineated molecular pathways associated with cancer cachexia–related muscle atrophy; it did not test FST344 or establish direct follistatin effects in humans [pubmed:39116208].
• Protein–protein interaction: Follistatin was identified as an angiogenin-binding protein, a mechanistic interaction observed outside of human outcome trials [pubmed:17991437].
• Engineered variant PK/PD (not FST344): A pharmacokinetic/pharmacodynamic study characterized an engineered human follistatin variant in nonclinical settings; it is not FST344 and is not human interventional evidence [crossref:10.1124/jpet.112.0313hia].
• Forensic detection: Analytical studies detected “black market” FST344 in market/seized samples, indicating detectability but not informing product quality, dosing, safety, efficacy, or prevalence [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

What Is Not Established (Limits of This Packet)

• No interventional human trials of exogenous FST344 are included in this packet.
• No randomized clinical trial evidence demonstrates clinical benefit or a defined safety profile for FST344 in broad indications.
• No dosing, delivery, or regimen guidance is supported by the supplied literature.
• Preclinical and mechanistic plausibility do not constitute proof of human efficacy or safety.
• Broad claims (e.g., generalized anti-aging or multi-organ benefits) are unsupported by this packet.
• Findings for total follistatin or FSTL3 should not be assumed to apply to the specific FST344 isoform without direct evidence.
• Forensic detection of black-market FST344 does not speak to quality control, safety, dosing, or real-world effectiveness.
• Conclusions should remain anchored to the specific human populations and endpoints studied [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].

FAQ

• What is Follistatin-344 (FST344)?
• FST344 refers to a 344–amino-acid isoform of the follistatin protein, which binds activins and related TGF-β ligands. Most literature in this packet addresses follistatin broadly rather than FST344-specific outcomes [pubmed:9785474; pubmed:15253386].
• Are there human trials testing exogenous FST344?
• No interventional human studies of exogenous FST344 are included in this packet.
• What human evidence is available?
• Observational, disease-specific studies report follistatin as a biomarker/target in FLT3/ITD AML, measure circulating follistatin in steatotic liver disease, and report higher serum levels in ovarian endometriosis; none test exogenous FST344 [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].
• Can findings about FSTL3 be applied to FST344?
• No. FSTL3 is distinct from follistatin and shows differential actions; its findings are not interchangeable with those for follistatin/FST344 [pubmed:15451564; pubmed:37739334].
• Do black-market detection studies tell us anything about safety or dosing?
• No. These analytical reports document detection of FST344 in samples but do not inform dosing, safety, efficacy, or prevalence [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

References

• [pubmed:32134197]
• [pubmed:37757973]
• [crossref:10.1016/s1090-798x(10)79409-1]
• [pubmed:9785474]
• [pubmed:10077456]
• [pubmed:37739334]
• [pubmed:15253386]
• [pubmed:31322318]
• [pubmed:21353885]
• [pubmed:15451564]
• [pubmed:39116208]
• [pubmed:17991437]
• [crossref:10.1124/jpet.112.0313hia]
• [pubmed:31758732]
• [crossref:10.1002/dta.2741]
• [crossref:10.1002/dta.2882]